Found: 48
Select item for more details and to access through your institution.
CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.
- Published in:
- Cancer Gene Therapy, 2013, v. 20, n. 7, p. 386, doi. 10.1038/cgt.2013.35
- By:
- Publication type:
- Article
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 5, p. 1448, doi. 10.1007/s10637-020-00915-4
- By:
- Publication type:
- Article
An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome.
- Published in:
- European Journal of Haematology, 2018, v. 100, n. 1, p. 88, doi. 10.1111/ejh.12987
- By:
- Publication type:
- Article
Correction to: Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.
- Published in:
- Cancer Imaging, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s40644-022-00513-y
- By:
- Publication type:
- Article
VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation.
- Published in:
- FASEB Journal, 2015, v. 29, n. 1, p. 227, doi. 10.1096/fj.14-250985
- By:
- Publication type:
- Article
αB-Crystallin regulates expansion of CD11b<sup>+</sup>Gr-1<sup>+</sup> immature myeloid cells during tumor progression.
- Published in:
- FASEB Journal, 2013, v. 27, n. 1, p. 151, doi. 10.1096/fj.12-213017
- By:
- Publication type:
- Article
Genetically engineered T cells for the treatment of cancer.
- Published in:
- Journal of Internal Medicine, 2013, v. 273, n. 2, p. 166, doi. 10.1111/joim.12020
- By:
- Publication type:
- Article
Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity.
- Published in:
- Gene Therapy, 2015, v. 22, n. 7, p. 596, doi. 10.1038/gt.2015.41
- By:
- Publication type:
- Article
Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4.
- Published in:
- Gene Therapy, 2012, v. 19, n. 10, p. 988, doi. 10.1038/gt.2011.176
- By:
- Publication type:
- Article
Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients.
- Published in:
- Frontiers in Immunology, 2018, p. 1, doi. 10.3389/fimmu.2017.01956
- By:
- Publication type:
- Article
Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy.
- Published in:
- Laboratory Animals, 2005, v. 39, n. 4, p. 384, doi. 10.1258/002367705774286475
- By:
- Publication type:
- Article
281. Adenovirus-Mediated CD40 Ligand Therapy Induces Tumor Cell Apoptosis and Systemic Immunity in the TRAMP-C2 Mouse Prostate Cancer Model.
- Published in:
- Molecular Therapy, 2006, v. 13, p. S107, doi. 10.1016/j.ymthe.2006.08.335
- By:
- Publication type:
- Article
Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis.
- Published in:
- PLoS ONE, 2022, v. 17, n. 9, p. 1, doi. 10.1371/journal.pone.0271293
- By:
- Publication type:
- Article
CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes.
- Published in:
- Cancer Gene Therapy, 2014, v. 21, n. 3, p. 95, doi. 10.1038/cgt.2014.2
- By:
- Publication type:
- Article
Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.
- Published in:
- Cancer Gene Therapy, 2013, v. 20, n. 12, p. 702, doi. 10.1038/cgt.2013.76
- By:
- Publication type:
- Article
Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas.
- Published in:
- Cancer Gene Therapy, 2009, v. 16, n. 11, p. 848, doi. 10.1038/cgt.2009.31
- By:
- Publication type:
- Article
In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
- Published in:
- Cancer Gene Therapy, 2002, v. 9, n. 10, p. 846, doi. 10.1038/sj.cgt.7700507
- By:
- Publication type:
- Article
Mebendazole is unique among tubulin-active drugs in activating the MEK–ERK pathway.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41598-020-68986-0
- By:
- Publication type:
- Article
Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-54438-x
- By:
- Publication type:
- Article
Human urinary bladder carcinomas express adenovirus attachment and internalization receptors.
- Published in:
- Gene Therapy, 2002, v. 9, n. 9, p. 547, doi. 10.1038/sj.gt.3301689
- By:
- Publication type:
- Article
Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue.
- Published in:
- Acta Oncologica, 2009, v. 48, n. 3, p. 391, doi. 10.1080/02841860802438495
- By:
- Publication type:
- Article
Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia.
- Published in:
- PLoS ONE, 2013, v. 8, n. 1, p. 1, doi. 10.1371/journal.pone.0055818
- By:
- Publication type:
- Article
The immunotherapy of prostate and bladder cancer.
- Published in:
- BJU International, 2005, v. 96, n. 5, p. 728, doi. 10.1111/j.1464-410X.2005.05772.x
- By:
- Publication type:
- Article
Reply to ‘Enhanced CD28 signaling may be a common mechanism underlying resistance to regulation’ by E Wohlfert and Clark RB.
- Published in:
- 2007
- By:
- Publication type:
- Letter
Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells.
- Published in:
- Leukemia (08876924), 2006, v. 20, n. 10, p. 1819, doi. 10.1038/sj.leu.2404366
- By:
- Publication type:
- Article
Assessing tissue damage in multiple sclerosis: a biomarker approach.
- Published in:
- Acta Neurologica Scandinavica, 2014, v. 130, n. 2, p. 81, doi. 10.1111/ane.12239
- By:
- Publication type:
- Article
A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-88433-y
- By:
- Publication type:
- Article
Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis.
- Published in:
- Immunology, 2014, v. 142, n. 3, p. 431, doi. 10.1111/imm.12275
- By:
- Publication type:
- Article
T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis.
- Published in:
- Immunology, 2013, v. 140, n. 2, p. 211, doi. 10.1111/imm.12129
- By:
- Publication type:
- Article
T regulatory cells in B-cell malignancy - tumour support or kiss of death?
- Published in:
- Immunology, 2012, v. 135, n. 4, p. 255, doi. 10.1111/j.1365-2567.2011.03539.x
- By:
- Publication type:
- Article
Both CD4.
- Published in:
- Immunology, 2011, v. 133, n. 3, p. 296, doi. 10.1111/j.1365-2567.2011.03439.x
- By:
- Publication type:
- Article
T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies.
- Published in:
- Immunology, 2010, v. 131, n. 3, p. 371, doi. 10.1111/j.1365-2567.2010.03308.x
- By:
- Publication type:
- Article
The T-cell pool is anergized in patients with multiple sclerosis in remission.
- Published in:
- Immunology, 2009, v. 126, n. 1, p. 92, doi. 10.1111/j.1365-2567.2008.02881.x
- By:
- Publication type:
- Article
Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 10, p. 2851, doi. 10.1007/s00262-021-02895-7
- By:
- Publication type:
- Article
Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand.
- Published in:
- Cancer Immunology, Immunotherapy, 2014, v. 63, n. 3, p. 273, doi. 10.1007/s00262-013-1507-6
- By:
- Publication type:
- Article
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses.
- Published in:
- Frontiers in Immunology, 2020, v. 11, p. 1, doi. 10.3389/fimmu.2020.00940
- By:
- Publication type:
- Article
Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer.
- Published in:
- Neuroendocrinology, 2017, v. 105, n. 1, p. 54, doi. 10.1159/000448430
- By:
- Publication type:
- Article
CD40 stimulation via CD40 ligand enhances adenovirus‐mediated tumour immunogenicity including 'find‐me', 'eat‐me', and 'kill‐me' signalling.
- Published in:
- Journal of Cellular & Molecular Medicine, 2024, v. 28, n. 7, p. 1, doi. 10.1111/jcmm.18162
- By:
- Publication type:
- Article
Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles.
- Published in:
- Viruses (1999-4915), 2015, v. 7, n. 11, p. 5780, doi. 10.3390/v7112899
- By:
- Publication type:
- Article
Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition.
- Published in:
- BMC Research Notes, 2019, v. 12, n. 1, p. N.PAG, doi. 10.1186/s13104-019-4273-5
- By:
- Publication type:
- Article
Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.
- Published in:
- PLoS ONE, 2015, v. 10, n. 12, p. 1, doi. 10.1371/journal.pone.0144787
- By:
- Publication type:
- Article
Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models.
- Published in:
- Journal of Translational Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12967-023-04374-2
- By:
- Publication type:
- Article
Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer.
- Published in:
- Journal of Translational Medicine, 2016, v. 14, p. 1, doi. 10.1186/s12967-016-1037-z
- By:
- Publication type:
- Article